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The c-myc proto-oncogene plays a key role in the proliferation, differentiation, apoptosis, and regulation of
the cell cycle. Recently, it was demonstrated that the 5 nontranslated region (5 NTR) of human c-myc mRNA
contains an internal ribosomal entry site (IRES). In this study, we investigated cellular proteins interacting
with the IRES element of c-myc mRNA. Heterogeneous nuclear ribonucleoprotein C (hnRNP C) was identified
as a cellular protein that interacts specifically with a heptameric U sequence in the c-myc IRES located between
two alternative translation initiation codons CUG and AUG. Moreover, the addition of hnRNP C1 in an in vitro
translation system enhanced translation of c-myc mRNA. Interestingly, hnRNP C was partially relocalized
from the nucleus, where most of the hnRNP C resides at interphase, to the cytoplasm at the G2/M phase of the
cell cycle. Coincidently, translation mediated through the c-myc IRES was increased at the G2/M phase when
cap-dependent translation was partially inhibited. On the other hand, a mutant c-myc mRNA lacking the
hnRNP C-binding site, showed a decreased level of translation at the G2/M phase compared to that of the
wild-type message. Taken together, these findings suggest that hnRNP C, via IRES binding, modulates
translation of c-myc mRNA in a cell cycle phase-dependent manner.
The c-myc proto-oncogene participates in various cellular
events including proliferation, differentiation, apoptosis, cell
cycle, and regulation of mammalian body size (14, 27, 50, 60).
The c-myc mRNA encodes a helix-loop-helix–leucine zipper
class transcription factor that binds to E-box (CAGGTG) pro-
moter sequences in conjunction with its dimerization partner
Max. Myc-Max heterodimers function as transcriptional acti-
vators of critical target genes (3, 4, 13). Regulation of c-myc
expression occurs at multiple levels, including transcription
(36), stability of both the mRNA and protein (49), and trans-
lation (41, 56).
The human c-myc transcripts are generated from four alter-
native promoters (P0, P1, P2, and P3). In normal cells, tran-
scription of most of the c-myc mRNA (75 to 90%) is directed
by the P2 promoter (5, 6). P2 mRNA directs translation of two
distinct proteins of 67- and 64-kDa, designated c-Myc1 and
c-Myc2, respectively, by an alternative initiation mechanism
involving two in-frame start codons, CUG and AUG, residing
at nt 364 and 409, respectively (20). Recently, there have been
reports suggesting that the 5 nontranslated region (5NTR) of
c-myc contains an internal ribosomal entry site (IRES) (41,
56). In the human c-myc mRNA, the IRES lies in the 5 NTR
upstream of the AUG start codon of the major c-Myc protein
(c-Myc2) (Fig. 1A and see below). Moreover, translation of
c-myc mRNA was shown to occur via a cap-dependent mech-
anism as well as an IRES-dependent mechanism (57).
The IRES is a specialized RNA structure that recruits the
ribosome to the mRNA in a cap-independent manner. After
the discovery of IRESs from picornavirus mRNAs (31, 44),
several viral and cellular mRNAs have been shown to contain
IRESs (22, 61). Studies of factors required for IRES-depen-
dent translation reveal that canonical translation initiation fac-
tors and RNA-binding proteins such as poly(rC)-binding pro-
tein, polypyrimidine tract-binding protein (PTB), upstream of
N-ras (unr), and the autoantigen La are required for transla-
tion of certain IRES-containing mRNAs (8, 23, 29, 37). The
demand for the canonical and mRNA-specific initiation factors
varies among IRES-containing mRNAs (32).
Much of what we have learned about mRNA-specific trans-
lation factors has been derived from virus expression studies.
The La autoantigen, also known as the transcription termina-
tion factor of RNA polymerase III (17), stimulates translation
of poliovirus RNA and reduces aberrant translation (37). La
also binds to the initiation codon of the hepatitis C virus IRES
to enhance translation (2). PTB, also known as heterogeneous
nuclear ribonucleoprotein I (hnRNP I), is a negative regulator
of pre-RNA splicing (15, 43) and was suggested to augment
IRES-dependent translation of picornavirus mRNAs.
Poly(rC)-binding protein, also known as hnRNP E, is required
for IRES-dependent translation of poliovirus and hepatitis A
virus RNAs (8, 18). unr, another cellular factor, is required for
efficient translation of human rhinovirus mRNA (29).
Several cellular mRNAs also contain IRESs. The list of
IRES-containing mRNAs includes multifunctional c-myc (41,
56), proto-oncogene platelet-derived growth factor 2
(PDGF2)/c-sis (7), cell survival- and death-related X-linked
inhibitor of apoptosis (25), apoptotic protease-activating factor
1 (11), the growth regulators fibroblast growth factor 2 (62)
and vascular endothelial growth factor (28), ornithine decar-
boxylase (47), and p58PISTLRE (12), etc. For further informa-
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tion, an IRES database is available at http://www.rangueil
.inserm.fr/iresdatabase.
Several RNA-binding proteins have been shown to augment
cellular IRES-dependent translation. For instance, the La au-
toantigen regulates the translation of X-linked inhibitor of
apoptotis mRNA (24). Apoptotic protease-activating factor 1
IRES activity is enhanced by overexpression of PTB and unr in
cell lines deficient in these molecules (40). RNA-binding pro-
teins also may have inhibitory effects on IRES-dependent
translation. For example, PTB inhibits translation of BiP
FIG. 1. Detection of cellular proteins interacting with the human c-myc IRES. (A) Schematic diagram of the 5 leader of human c-myc P2
transcript used in the UV cross-linking assay. Transcription and translation start sites are depicted by the arrows with open and solid heads,
respectively. Transcript I (nt 1 to 366) spans from the transcription start site to the minor translation initiation codon CUG364, indicated by an open
triangle, used in the translation of c-Myc1. Transcript II (nt 1 to 411) spans from the transcription start site to the major translation initiation codon
AUG409, indicated by a solid triangle, used in the translation of c-Myc2. The position of the heptameric U sequence is indicated by UUUUUUU.
(B) UV cross-linking experiments with 32P-labeled transcripts I and II. HeLa S3 cell cytoplasmic extracts were incubated with 32P-labeled RNA
probes I and II without competitor RNAs (lanes 1 and 2). Competition experiments were carried out with RNA probe II in the presence of
competitor RNAs. For RNA competition, 50 ng of four homopolymeric RNAs [poly(A), poly(C), poly(G), and poly(U)] (lanes 3 to 6) and a 50-fold
molar excess of unlabeled transcript II (lane 7) were included in the binding reaction mixtures. After UV-irradiation, samples were treated with
RNase cocktail before analysis by SDS–12% PAGE.
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mRNA (34). Despite the many examples of IRES-dependent
translation, the detailed mechanism of modulation of IRES-
dependent translation by RNA-binding proteins remains to be
elucidated.
We therefore sought to identify the cellular protein(s) re-
quired for translation of c-myc mRNA via the IRES element.
We found that hnRNP C could interact with a heptameric U
sequence within the IRES of c-myc mRNA. Moreover, coex-
pression of hnRNP C1 in a rabbit reticulocyte lysate (RRL)
enhanced translation of c-myc mRNA in a heptameric U se-
quence-dependent manner. Interestingly, hnRNP C was par-
tially redistributed between the nucleus and cytoplasm in a cell
cycle phase-dependent manner. At the interphase, most of
hnRNP C resided in the nucleus, whereas a portion of hnRNP
C migrated to the cytoplasm at the G2/M phase. Concomi-
tantly, translation of c-myc mRNA was enhanced relative to
translation of a mutant c-myc mRNA lacking the hnRNP C-
binding site. These data indicate that the c-myc IRES-depen-
dent translation is regulated by hnRNP C in a cell cycle phase-
dependent manner.
MATERIALS AND METHODS
Plasmid construction. The 5 NTR and a portion of the c-Myc protein-
encoding region of the human c-myc P2 transcript fragment (nucleotides [nt] 1 to
531 of the P2 transcript) were obtained by PCR of a human fetal liver cDNA
library (Clontech) with the primers 5-CCATCGATAACTCGCTGTAGTAAT
TCCAGCG-3 and 5-AACTGCAGCTCGCTCTGCTGCTG-3. The resulting
clone contains 41 amino acids of the c-Myc2 N-terminal coding region. The
cDNA corresponding to the c-myc P2 transcript was cloned into the reporter
plasmid pSK()/CAT-ICS-CAT (34) digested with ClaI and PstI in order to
generate pCAT-M531CAT. Plasmid pM531CAT was generated by treating
pCAT-M531CAT with ClaI, Asp718, Klenow, and T4 DNA ligase consecu-
tively. In order to generate a mutant clone with changes in the c-myc IRES from
UUUUUUU to CUUCUUC, a PCR was performed with plasmid pCAT-
M531CAT as a template and oligonucleotides 5-GGGGTACCAGCTGCTTA
GACGCTGGACTTCTTCCGGGTAGTG-3 and 5-GCTCTAGATTATCACT
TATTCAGG-3 as primers. The amplified DNA fragment was digested with
KpnI and XbaI and then cloned into plasmid pSK() (Stratagene) to generate
pMPvu(U‹C)CAT. Plasmid pCAT-M531(U‹C)CAT, which has the U-to-C
changes in the heptameric U sequence, was generated by an insertion of the
PvuII-XbaI fragment of pMPvu(U‹C)CAT and the PvuII-ClaI fragment of
pCAT-M511CAT into pSK()/CAT-ICS-CAT digested with ClaI and XbaI.
The dicistronic constructs pCAT-M411CAT, pCAT-M366CAT, and pCAT-
M411(U‹C)CAT were generated from PCR products. A common primer 5-C
CATCGATAACTCGCTGTAGTAATTCCAGCG-3 was used in each of the
PCRs together with the following specific primers and templates to generate the
three different constructs. The specific primer 5-CGGGATCCCATCGTCGCG
GGAGGCTGCTG-3 and template pCAT-M531CAT were used to generate
pCAT-M411CAT, the specific primer 5-CGGGATCCCAGCGTCTAAGCA
GCTGCAAG-3 and template pCAT-M531CAT were used to generate
pCAT-M366CAT, and the specific primer 5-CGGGATCCCATCGTCGCGG
GAGGCTGCTG-3 and template pCAT-M531(U‹C)CAT were used to gen-
erate pCAT-M411(U‹C)CAT. For the generation of monocistronic con-
structs, plasmids pCAT-M411CAT, pCAT-M366CAT, and pCAT-
M411(U‹C)CAT were treated with ClaI-Asp718-Klenow and self-ligated. For in
vivo analyses, dicistronic constructs under the control of the cytomegalovirus
(CMV) promoter were generated by inserting the c-myc IRES in the intercis-
tronic region between the Renilla luciferase and firefly luciferase reporter genes.
Plasmids pCAT-M531CAT and pCAT-M531(U‹C)CAT were treated with
XhoI-BamHI-Klenow, and the DNA fragments containing the c-myc IRES were
isolated and ligated into the pGL3 control vector (Promega) treated with NcoI-
Klenow to generate pGL3-M531 and pGL3-M511(U‹C). pGL3-M511 and
pGL3-M531(U‹C) were treated with HindIII-XbaI-Klenow, and then the DNA
fragments containing the c-myc IRES and the firefly luciferase reporter were
isolated. These DNA fragments were ligated with pRL-CMV (Promega) treated
with XbaI-Klenow to generate the dicistronic constructs pRM531F and
pRM531(U‹C)F. The construction procedure for plasmid pGEX-KG/hnRNP
C1 (1-290) was described previously (33). All mutations in the various constructs
were verified by DNA sequencing.
Cell culture, synchronization, fluorescence-activated cell sorter analysis, and
transient transfection. HeLa cells were cultured in Dulbecco’s modified Eagle’s
medium (Gibco-BRL) supplemented with 10% fetal bovine serum (complete
medium; Clontech). For cell cycle synchronization, G1/S-phase HeLa cells were
obtained by a double-thymidine block (59). The cells were synchronized at the
G2/M boundary by a double-thymidine block, released for 6 h, and then exposed
to nocodazole (0.2 g/ml; Sigma) (59). Synchronized HeLa cells were harvested
and fixed with cold 100% ethanol. Fixed cells were stained with propidium iodide
(40 g/ml; Sigma) and treated with RNase A (50 g/ml; Sigma) for 30 min at
room temperature. Samples of 104 cells were analyzed for DNA content on a
FACScan (Becton-Dickinson). Transient transfections were performed by elec-
troporation 12 h prior to the thymidine block.
Purification of recombinant GST-hnRNP C1. Recombinant glutathione S-
transferase (GST)-fused hnRNP C1 (nt 1 to 290) (GST-hnRNP C1) was ex-
pressed in the Escherichiacoli strain BL21(DE3)/pLysS by using plasmid pGEX-
KG/hnRNP C1 (1-290). After induction of GST-hnRNP C1 by the addition of
isopropyl--D-thiogalactopyranoside, cells were harvested and resuspended in
lysis buffer (20 mM Na-phosphate [pH 7.6], 300 mM NaCl, 0.5 mM phenylmeth-
ylsulfonyl fluoride [PMSF], 10 mM -mercaptoethanol, 10% [vol/vol] glycerol).
GST fusion proteins were allowed to bind to glutathione-Sepharose 4B resin
(Amersham-Pharmacia Biotech) in lysis buffer for 2 h at 4°C. GST-hnRNP C1
protein was eluted by 10 mM reduced glutathione (Roche). The fractions con-
taining GST-hnRNP C1 were loaded onto a poly(U)-Sepharose 4B column
(Amersham-Pharmacia Biotech). After the column was washed with 0.1 M NaCl
binding buffer (20 mM Na-phosphate [pH 7.6], 100 mM NaCl, 0.5 mM PMSF, 10
mM -mercaptoethanol, 10% [vol/vol] glycerol), the GST-hnRNP C1 was eluted
with 1.0 M NaCl.
Preparation of HeLa cell lysates. Cytoplasmic extract (S10) of HeLa S3 cells
for UV cross-linking, immunoprecipitation, and pull-down assay was prepared as
described by Oh et al. (42). To obtain asynchronous and synchronized HeLa cell
extracts, asynchronous or synchronized HeLa cells from a 100-mm-diameter dish
were trypsinized, rinsed with phosphate-buffered saline (PBS), incubated in 200
l of hypotonic buffer (10 mM HEPES [pH 7.9], 10 mM KCl, 1.5 mM MgCl2)
supplemented with a 0.5 mM protease inhibitor PMSF on ice, and lysed by the
addition of 25 l of hypotonic buffer containing 2.5% Nonidet P-40 (NP-40) and
PMSF. The samples were freeze-thawed five times and centrifuged at 850  g for
10 min. Cytosolic fractions were prepared with an additional high-speed centrif-
ugation of cytoplasmic fractions at 12,000  g for 30 min, and the supernatants
were kept for analysis. For preparing nuclear fractions, nuclear pellets were
incubated in extraction buffer (20 mM HEPES [pH 7.9], 0.45 M NaCl, 1 mM
EDTA) with protease inhibitors and centrifuged at 12,000  g for 10 min, and
the supernatants were kept for analysis.
Generation of biotinylated RNAs and RNA pull-down assay. For the genera-
tion of biotinylated RNA probes, 5 g of the monocistronic constructs
pM366CAT, pM411CAT, pM531CAT, pM411(U‹C)CAT, and pM531(U‹C)
CAT were linearized by using the following restriction enzymes: BamHI for
pM366CAT, pM411CAT, and pM411(U‹C)CAT and SmaI for pM531CAT and
pM531(U‹C)CAT. RNA transcripts were produced by T7 RNA polymerase
(Stratagene) with nucleoside triphosphates in biotinylation composition buffer
(0.5 mM [each] ATP, CTP, GTP, and UTP and 0.05 mM Bio-21-UTP [Strat-
agene]). After a 2-h incubation at 37°C, 5 U of RNase-free DNase (Promega)
was added to remove template plasmids. RNA pull-down experiments were
performed by using cytoplasmic extracts of HeLa S3 cells and biotinylated RNAs
corresponding to wild-type c-myc RNAs (nt 1 to 531, 1 to 411, and 1 to 366) and
to mutant c-myc RNAs [nt 1 to 531(U‹C) and 1 to 411(U‹C)]. After incubation
of the biotinylated RNAs (4 g) and the HeLa S3 cell cytoplasmic extracts (50
g) in 1 ml of incubation buffer (10 mM HEPES [pH 7.4], 1.5 mM magnesium
acetate, 90 mM potassium acetate, 2.5 mM dithiothreitol [DDT], 0.05% NP-40)
for 30 min at 4°C, the samples were subjected to streptavidin-agarose resin
(Pierce) adsorption and further incubated for 2 h. As nonspecific competitors, 8
g of yeast tRNAs (Roche) was added in the binding mixtures. After incubation,
the resin was washed four times with incubation buffer, and then the resin-bound
proteins were resolved by sodium dodecyl sulfate–12% polyacrylamide gel elec-
trophoresis (SDS–12% PAGE). Immunoblot analysis was performed by using an
hnRNP C-specific monoclonal antibody (4F4; a generous gift from Gideon
Dreyfuss, University of Pennsylvania, Philadelphia).
In vitro mRNA synthesis. The dicistronic constructs pRM531F and
pRM531(U‹C)F were linearized with the restriction enzyme HpaI. Transcripts
were generated in vitro from the linearized plasmids with T7 RNA polymerase
in the presence of m7G(5)pppG(5) (Amersham-Phamacia Biotech) according
to the manufacturer’s protocol. Capped mRNA was extracted with phenol-
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chloroform and then precipitated with ethanol. The plasmids pHC12, which
contains hnRNP C1 cDNA, and pT7-7/PTB1, which contains PTB1 cDNA, were
linearized with StyI and SalI, respectively. In vitro transcription was carried out
with the respective linearized plasmids with SP6 RNA polymerase (Roche) and
T7 RNA polymerase. The amount of mRNA was measured by optical absor-
bance at 260 nm, and the integrity of mRNA was verified by agarose gel elec-
trophoresis.
UV cross-linking. 32P-labeled RNA probes were synthesized by in vitro tran-
scription and isolated by push column chromatography (Stratagene). 32P-labeled
RNAs (3  105 cpm) were incubated with 20 g of HeLa cell extracts or 100 ng
of purified GST-hnRNP C1 dialyzed in the translation buffer (16 mM HEPES
[pH 7.5], 36 mM KCl, 169 mM potassium acetate, 1.2 mM magnesium acetate,
1.6 mM DTT, 2.8 mM -mercaptoethanol) with or without unlabeled c-myc
RNAs or homopolymeric ribonucleotides [poly(A), poly(C), poly(G), and
poly(U); Amersham-Pharmacia Biotech]. The RNA-protein mixture binding re-
action was carried out in a 30-l reaction mixture containing 0.5 mM DTT, 5 mM
HEPES (pH 7.6), 75 mM KCl, 2 mM MgCl2, 0.1 mM EDTA, 4% glycerol, 20 U
of RNasin (Promega), and 3 g of yeast tRNA. After 20 min of incubation at
30°C, the samples were irradiated with UV on ice for 15 min with a UV-
Stratalinker (Stratagene). Unbound RNAs were digested with 5 l of RNase
cocktail (2 l of RNase A [10 mg/ml], 2 l of RNase T1 [100 U/ml; Roche], 1 l
of RNase V1 [700 U/ml; Amersham-Pharmacia Biotech]) at 37°C for 45 min and
then analyzed by SDS–10 to 12% PAGE.
Immunoprecipitation of UV cross-linked proteins. For UV cross-linking and
immunoprecipitation assays, the samples were precleared by centrifugation in a
microcentrifuge for 5 min at 12,000  g following RNase cocktail treatment.
Then 1.5 l of c-Myc protein-specific monoclonal antibody (9E10; Santa Cruz) or
anti-hnRNP C monoclonal antibody (4F4) was added to the preloaded sample
diluted in 1 ml of immunoprecipitation buffer (20 mM HEPES [pH 7.4], 125 mM
KCl, 0.05% NP-40, 0.5 mM DTT, 0.5 mM PMSF, and 0.5 mM EDTA). After a
2-h incubation at 4°C in a rotary mixer, 30 l of protein G-agarose slurry (Roche)
was added and incubated further for 2 h. After washing four times with 1 ml of
immunoprecipitation buffer, resin-bound proteins were detached from the beads
by adding 30 l of Laemmli sample buffer and heating the mixture to 100°C for
5 min and then the proteins were resolved on an SDS–10% PAGE gel.
In vitro translation with RRL. In vitro translation assays were carried out as
described by Jackson and Hunt (30) with minor modifications. One milliliter of
RRL (Green Hectares) was treated with micrococcal nuclease (final concentra-
tion, 150 U/ml; Roche) at 20°C for 15 min in the presence of 20 M hemin
(Sigma), 50 g of creatine phosphokinase (Sigma)/ml, and 1 mM CaCl2. The
nuclease reaction was terminated with the addition of 10 l of 0.2 M EGTA.
After EGTA treatment, 12 l of calf liver tRNA solution (5 mg/ml; Novagen)
was added to the reaction mixture and mixed well. The resulting nuclease-treated
RRL was dispensed into 200-l aliquots and stored frozen in a liquid nitrogen
tank until use. For the synthesis of hnRNP C1 and PTB1 (a negative-control
RNA-binding protein), 14 l of nuclease-treated RRL was mixed with 1 l of an
amino acid mixture containing 1 mM concentrations of each amino acid, 1 l of
2 M KCl, 0.5 l of 20 mM MgCl2, 1 l of 0.2 M creatine phosphate, and 0.4 g
of mRNA encoding either hnRNP C1 or PTB1. The reaction volume was ad-
justed to 20 l by adding diethyl pyrocarbonate-treated H2O. Translation reac-
tions were carried out for 100 min at 30°C. For a negative control, the translation
reaction was performed in the absence of mRNA (mock RRL). To investigate
the effect of hnRNP C1 on c-myc IRES-dependent translation, the reporter
dicistronic mRNAs RM531F and RM531(U‹C)F (see Fig. 5A) were incubated
in fresh RRL with the addition of the RRL containing hnRNP C1 or PTB1
synthesized in vitro as described above. For the pretreatment of RNA-binding
proteins, 0.2 g of each reporter mRNA [RM531F and RM531(U‹C)F] was
incubated for 10 min at 30°C in 10 l of RNA-protein interaction mixture, which
was composed of 4 l of diethyl pyrocarbonate-treated H2O, 4 l of RRL
containing the newly synthesized hnRNP C1 or PTB1, and 2 l of RNA-binding
buffer (75 mM HEPES [pH 8.0], 50 mM KCl, 1 mM DTT, 50% glycerol).
Translation reactions of dicistronic mRNAs [RM531F and RM531(U‹C)F]
were initiated by the addition of 12.5 l of fresh nuclease-treated RRL-amino
acid mixture, 1 l of 2 M KCl, 0.5 l of 20 mM MgCl2, and 1 l of 0.2 M creatine
phosphate to 5 l of the RNA-protein interaction mixture. Translation reactions
were carried out at 30°C for 45 min. Translation reactions through cap- and
IRES-dependent mechanisms were monitored by Renilla and firefly luciferase
activities, respectively. All translation reactions were performed at least three
times to obtain standard deviations and mean values.
Cellular RNA purification and Northern blot analysis. Expression of dicis-
tronic mRNA was analyzed by the Northern blot method with a probe specific for
firefly luciferase. A 32P-labeled probe was generated by using a random primer
labeling system (rediprime II; Amersham-Pharmacia Biotech) according to the
manufacturer’s instructions. Unincorporated 32P was removed by passing the
sample through a push column. Plasmids containing the wild-type and mutant
forms of c-myc IRESs were transfected into semiconfluent HeLa cells by using
Lipofectamine (Gibco-BRL) 18 h prior to synchronization. After transfection
and synchronization, total RNA was harvested from HeLa cells by using the TRI
reagent (Molecular Research Center) according to manufacturer’s directions.
After polyadenosine-containing [poly(A)] mRNAs were purified by using oli-
go(dT) cellulose (Amersham-Pharmacia Biotech), 2 g of poly(A) mRNAs
were resolved on 1.3% agarose gels in the presence of formaldehyde and 3-(N-
morpholino)propanesulfonic acid buffer and then blotted onto a nylon mem-
brane (Qiagen). Hybridization was carried out in hybridization buffer (10%
polyethylene glycol, 7% SDS, 1 mM EDTA, 250 mM NaCl, 80 mM Na2HPO4
[pH 7.3], salmon sperm single-stranded DNA [Sigma]) with 2  104 cpm of
32P-labeled probe/ml. After an 18-h incubation at 67°C, the nylon membrane was
washed and then subjected to autoradiography.
Reporter gene analysis. The dicistronic constructs, which contain wild-type or
mutant c-myc IRES were cotransfected with pCMV●SPORT-gal (Invitrogen)
to HeLa cells by using electroporation. After synchronization, cells were har-
vested and freeze-thawed for three cycles. To obtain the cytoplasmic extract,
centrifugation was carried out at 10,000  g for 10 min. Aliquots of in vitro-
translated RRL were diluted with PBS. The cytoplasmic extracts and PBS-
diluted RRLs were analyzed with a dual luciferase reporter assay system (Pro-
mega) according to the manufacturer’s instructions. The transfection efficiency
was also determined for each luciferase value relative to that of the transfection
control -galactosidase activity.
Immunoblot analysis. Immunoblot analysis was performed with monoclonal
antibodies against hnRNP C, PTB, actin (ICN Biomedicals), and poly(ADP-
ribose) polymerase (PARP; Santa Cruz) as primary antibodies and a horseradish
peroxidase-linked anti-mouse immunoglobulin G as a secondary antibody. Mem-
brane-bound antibodies were detected by enhanced chemiluminescence (Amer-
sham-Pharmacia Biotech).
RESULTS
Identification of a 40-kDa protein that interacts with the
human c-myc IRES. To identify cellular factor(s) interacting
with the c-myc IRES, a UV cross-linking experiment was per-
formed with HeLa S3 cell cytoplasmic extracts and 32P-labeled
c-myc RNAs I (nt 1 to 366) and II (nt 1 to 411) shown in Fig.
1A. Four cellular proteins with apparent molecular masses of
40, 52, 65, and 110 kDa were found to bind to c-myc RNA II
(nt 1 to 411) (Fig. 1B, lane 1). In contrast, the binding to RNA
I (nt 1 to 366) was dramatically and specifically reduced for the
40-kDa protein while identical binding was observed for the
other three proteins of 52, 65, and 110-kDa (Fig. 1B, compare
lanes 1 and 2). These binding data indicate that the c-myc RNA
region between nt 367 and 411 is required for the strong
interaction with the 40-kDa protein.
The specificity of RNA-binding activity was investigated by
adding unlabeled competitor RNA II (nt 1 to 411) to the UV
cross-linking reaction mixture. Binding of the 40-kDa protein
was the most sensitive to competition, essentially abolishing
binding activity to the RNA II probe (Fig. 1B, lane 7). When
homopolymeric ribonucleotides were used as competitors in
the UV cross-linking reaction mixtures, poly(U) and poly(G)
but not poly(A) and poly(C) strongly inhibited binding of the
40-kDa protein to the c-myc IRES (Fig. 1B, lanes 3 to 6). The
40-kDa protein was further characterized because it binds spe-
cifically to the c-myc IRES.
hnRNP C interacts with the heptameric U sequence in the
c-myc IRES. Our binding results indicate that the region be-
tween the two alternative translation initiation codons (nt 367
to 411) of c-myc RNA is required for the binding of the 40-kDa
protein (Fig. 1B, lanes 1 and 2). Moreover, poly(U) and
poly(G) RNAs can compete for this binding to the c-myc IRES
VOL. 23, 2003 hnRNP C MODULATES TRANSLATION OF c-myc mRNA 711
 o
n
 M
ay 7, 2015 by PO
STECH LIBRARY
http://m
cb.asm
.org/
D
ow
nloaded from
 
RNA (Fig. 1B, lanes 5 to 6). Both the molecular mass and
RNA-binding specificity of the 40-kDa protein are similar to
those of hnRNP C, a member of hnRNPs (58). Moreover,
hnRNP C was shown to bind strongly to U- and G-rich se-
quences by a systematic evolution of ligands by exponential
enrichment and competition binding assays (16, 54). These
analyses identified a U- and G-rich sequence (AGUAUUUU
UGUGGA) that is similar to a sequence present within the
high-affinity binding region of the 40-kDa protein in the c-myc
IRES (nt 365 to 381; UGGAUUUUUUUCGGGUA) (here-
after, we refer to this UUUUUUU sequence as the heptameric
U sequence). Therefore, we next examined whether the 40-
kDa protein is immunologically related to hnRNP C by immu-
noprecipitation of UV cross-linked proteins with 32P-labeled
c-myc RNA II (nt 1 to 411). The 40-kDa protein was detected
after immunoprecipitation of UV cross-linked proteins by a
specific monoclonal antibody against hnRNP C (4F4) (Fig. 2A,
lane 2). On the other hand, no band was detected when a
monoclonal antibody against c-Myc protein (9E10) was used as
a negative control (Fig. 2A, lane 1). These data identify
hnRNP C as the 40-kDa protein that binds to the c-myc IRES.
The interaction between the c-myc IRES and hnRNP C was
confirmed by the UV cross-linking method with a purified
recombinant hnRNP C protein. We purified a recombinant
GST-hnRNP C1 from E. coli. As shown in Fig. 2B, GST-
hnRNP C1 strongly bound to probe II (nt 1 to 411) containing
the heptameric U sequence. In contrast, GST-hnRNP C1
bound poorly to probe I (nt 1 to 366) lacking the heptameric U
sequence (Fig. 2B, lane 1). The GST protein itself did not bind
to probe II (nt 1 to 411) (Fig. 2B, lane 3).
The interaction between hnRNP C and c-myc RNA was
further confirmed by competition assays. UV cross-linking ex-
periments with purified GST-hnRNP C1 and 32P-labeled c-myc
RNA were performed in the presence or absence of compet-
itor RNAs (Fig. 2C). The interaction between GST-hnRNP C1
and probe II was strongly inhibited by poly(U), poly(G), and
unlabeled c-myc RNA (nt 1 to 411) but not by poly(A),
poly(C), or unlabeled c-myc RNA (nt 1 to 366) lacking the
heptameric U sequence (Fig. 2C). These competition patterns
with purified GST-hnRNP C1 are well matched with the bind-
ing of the 40-kDa protein to c-myc RNA obtained by UV
cross-linking with a HeLa S3 cell cytoplasmic extract (compare
Fig. 1B with 2C). Taken together, these data indicate that
hnRNP C directly interacts with c-myc RNA and that a specific
RNA-protein interaction can occur in cells.
The heptameric U sequence resides at nt 369 to 375, which
is downstream of the minor translational initiation codon
CUG364 but upstream of the major translational initiation
codon AUG409. We next determined whether the heptameric
U sequence participates in the binding of hnRNP C since this
protein has a high affinity to oligo(U) (16). The heptameric U
sequence was changed to CUUCUUC while maintaining the
amino acid sequences of the c-Myc1 translated from CUG364
(Fig. 3A). The effect of the mutation on hnRNP C binding to
c-myc RNA was assessed by RNA pull-down assays (Fig. 3B)
or UV cross-linking experiments (Fig. 3C). In vitro pull-down
experiments were performed by using HeLa S3 cell cytoplas-
mic extracts and biotinylated c-myc RNAs (Fig. 3B). HnRNP C
was coprecipitated with wild-type c-myc RNAs containing the
intact heptameric U sequence such as c-myc RNA (nt 1 to 531)
and c-myc RNA (nt 1 to 411) (Fig. 3B, lanes 2 and 3), whereas
c-myc RNAs lacking the heptameric U sequence were not
associated with hnRNP C (Fig. 3B, lanes 4 to 6). We also found
that a biotinylated RNA of 45 nt corresponding to nt 367 to
411 was sufficient for binding to hnRNP C (data not shown).
Direct binding of hnRNP C to the heptameric U sequence
was assessed by using GST-hnRNP C1 and 32P-labled c-myc
RNAs (Fig. 3C). Purified GST-hnRNP C1 interacted strongly
with c-myc RNA containing the intact heptameric U sequence
(Fig. 3C, lanes 1 and 2) but weakly with mutant c-myc RNAs
with U-to-C changes (Fig. 3C, lanes 4 and 5). Together, these
data indicate that the heptameric U sequence is critical for the
binding of hnRNP C to the c-myc IRES.
hnRNP C specifically interacts with c-myc IRES in a cell
cycle phase-dependent manner. In normal cells, hnRNP C is
mainly confined to the nucleus (10), and therefore, its function
in translation is enigmatic, although several cytoplasmic roles
of hnRNP C have been reported (38, 48, 52, 63). Recently,
enrichment of hnRNP C in the cytoplasm has been reported at
a specific cell cycle phase and during differentiation (38, 52).
To investigate the role of hnRNP C in c-myc translational
regulation, we determined the level of hnRNP C at specific cell
cycle phases with synchronized HeLa cells. The proliferation of
HeLa cells was arrested at the specific cell cycle phases G1/S
and G2/M. Cell cycle progression was monitored by flow cy-
tometry. As shown in Fig. 4A, cells were predominantly ar-
rested at the G1/S phase (Fig. 4AII) and G2/M phase (Fig.
4AIII).
After synchronization, cells were harvested, and the cytoso-
lic and nuclear extracts were subjected to UV cross-linking
assays by using an RNA probe II (nt 1 to 411) (Fig. 1A)
containing the heptameric U sequence (Fig. 4B). The level of
hnRNP C in the cytosolic extracts was dramatically increased
in cells arrested at the G2/M phase (Fig. 4B, lane 3) compared
with cytosolic extracts of the asynchronized cells (lane 1) or
cells arrested at the G1/S phase (lane 2). The level of hnRNP
C in the nucleus remains at similar levels throughout the cell
cycle (lanes 4 to 6 in Fig. 4B).
The level of hnRNP C in the cytoplasm was also monitored
by immunoblot analysis (Fig. 4C). hnRNP C was dramatically
enriched in the cytoplasm at the G2/M phase compared to the
G1/S phase (Fig. 4C, compare lanes 3 and 2 of anti-hnRNP C).
Similar levels of hnRNP C were detected in the nucleus of the
asynchronized and synchronized cells (Fig. 4C, lanes 4 to 6 of
anti-hnRNP C). To confirm the total amounts of proteins and
the quality of fractionation of the cell extracts, levels of actin,
which is confined in the cytoplasm, and PARP, which is con-
fined in the nucleus, were monitored with anti-actin and anti-
PARP antibodies. As shown in Fig. 4C, actin and PARP were
detected mostly in the cytosolic (Fig. 4C, lanes 1 to 3) and
nuclear fractions (Fig. 4C, lanes 4 to 6), respectively, and levels
of these proteins remain the same throughout the cell cycle.
These data indicate that the fractionations of cell extracts were
accomplished properly and that the fluctuation of the level of
hnRNP C in the cell cycle is not a general phenomenon ob-
served for all proteins. Interestingly, PTB, which shuttles be-
tween the nucleus and the cytoplasm, was increased in the
cytoplasm at the G2/M phase even though the degree of fluc-
tuation in protein levels is much lower than that of hnRNP C
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FIG. 2. hnRNP C interacts with the c-myc IRES. (A) Immunoprecipitation of proteins labeled by UV cross-linking with 32P-labeled RNA probe
II (nt 1 to 411). After RNase cocktail treatment, samples were precleared with streptavidin-agarose resin and then a monoclonal antibody against
hnRNP C (4F4) (lane 2) or c-Myc protein (9E10) (lane 1) was added to the immunoprecipitation buffer. After immunoprecipitation, bound
proteins were resolved on an SDS–10% PAGE gel. Lane 3 shows the labeled proteins after UV cross-linking. (B) Direct binding of purified hnRNP
C1 to the c-myc IRES. One hundred nanograms of purified GST-hnRNP C1 and GST were UV cross-linked with RNA probes I and II (3  105
cpm), respectively. After UV-irradiation, samples were treated with RNase cocktail before being analyzed by SDS–12% PAGE. The arrow
represents the position of cross-linked GST-hnRNP C1 (65 kDa). GST-hnRNP C1 protein and GST protein were used in lanes 1 and 2 and lane
3 as protein sources, respectively. Transcripts I and II were used in lane 1 and lanes 2 and 3 as probes, respectively. (C) Effects of competitor RNAs
on binding of purified hnRNP C1 to probe II. One hundred nanograms of recombinant GST-hnRNP C1 was incubated with RNA probe II in the
UV cross-linking experiments (lanes 1 to 8). As competitor RNAs, 50 ng of four homopolymeric RNAs (lanes 2 to 5), 5 (lane 6)- and 50 (lane
7)-fold molar excesses of unlabeled transcript II, and a 50-fold molar excess of transcript I (lane 8) were added in the competition assays.
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FIG. 3. The heptameric U sequence plays a key role in the interaction with hnRNP C. (A) Schematic diagram of RNA transcripts used in RNA
pull-down experiments and UV cross-linking experiments. The elements are represented as described in the legend to Fig. 1A. In the constructs
of nt 1 to 411(U‹C) and nt 1 to 531(U‹C), there are nucleotide changes in the heptameric U sequence from UUUUUUU to CUUCUUC. The
amino acid sequence of the c-Myc1 protein remains the same even after the U-to-C mutation. (B) In order to investigate whether hnRNP C can
make a complex with the c-myc IRES, RNA pull-down experiments were performed by using cytoplasmic extracts of HeLa S3 cells and biotinylated
RNAs corresponding to wild-type c-myc RNAs (nt 1 to 531, 1 to 411, and 1 to 366 are shown on lanes 2 to 4, respectively) and to mutant c-myc
RNAs [nt 1 to 531(U‹C) and 1 to 411(U‹C) are shown on lanes 5 to 6]. After incubation of the biotinylated RNAs and the cytoplasmic extracts
in incubation buffer, the samples were subjected to streptavidin-agarose resin adsorption. After washing the resins, the resin-bound proteins were
resolved by an SDS–12% PAGE gel. Immunoblot analysis was performed by using an hnRNP C-specific monoclonal antibody (4F4). (C) UV
cross-linking experiments were performed with 100 ng of purified proteins (GST-hnRNP C1 [lanes 1 to 5] and GST [lane 6]) and 32P-labeled RNA
probes (3  105 cpm) corresponding to c-myc wild type (nt 1 to 531, 1 to 411, and 1 to 366 [lanes 1 to 3]) and mutant RNAs [nt 1 to 531(U‹C)
and 1 to 411(U‹C) (lanes 4 and 5)]. After UV-irradiation, samples were treated with RNase cocktail and then resolved by SDS–12% PAGE. The
arrow represents the position of cross-linked GST-hnRNP C1.
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(Fig. 4C). The fluctuation of hnRNP C levels during the cell
cycle phases was also shown by Millard et al. (38).
hnRNP C augments translation of c-myc mRNA at the G2/M
phase. In order to investigate the role of the hnRNP C binding
to c-myc IRES function, we generated dicistronic mRNA con-
structs containing the c-myc IRES or its variant at the inter-
cistronic regions of two consecutive genes, Renilla luciferase
and firefly luciferase (Fig. 5A). In these constructs, the firefly
luciferase and Renilla luciferase are produced by c-myc IRES-
dependent translation and cap-dependent translation, respec-
FIG. 4. The level of hnRNP C protein in the cytoplasm fluctuates in a cell cycle phase-dependent manner. (A) Synchronization of cells by the
chemical treatments was monitored by flow cytometry analysis of cells stained with propidium iodide. The G1 and G2 peaks are depicted as 1c and
2c, respectively. (B) For UV cross-linking experiments, 25 g of HeLa cell extract was incubated with a wild-type c-myc RNA probe II (nt 1 to
411) (Fig. 1A) labeled with 32P (3  105 cpm). Cytosolic (lanes 1 to 3) and nuclear (lanes 4 to 6) extracts were prepared from asynchronous
exponentially growing HeLa cells (Asyn.), G1/S phase-arrested cells (G1/S), and G2/M phase-arrested cells (G2/M). After UV-irradiation, samples
were treated with RNase cocktail and then resolved by SDS–12% PAGE. The arrow depicts the position of cross-linked hnRNP C. (C) Fluctuation
of hnRNP C level in the cytoplasm was monitored by immunoblot analysis. The cytosolic and nuclear fractions of HeLa cell extracts were prepared
as described for panel B. Fractionated HeLa cell extracts (20 g each) were analyzed by immunoblotting with specific monoclonal antibodies
against hnRNP C, PTB, actin, and PARP as shown in the rows anti-hnRNP C, -PTB, -actin, and -PARP, respectively.
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tively. HeLa cells were transfected with plasmid pRM531F,
which produces a dicistronic mRNA containing wild-type c-
myc IRES, or pRM531(U‹C)F, which produces a dicistronic
mRNA with the mutations in the heptameric U sequence in
the c-myc IRES. After transfection, the cells were synchro-
nized at the G1/S or G2/M phase and assessed for luciferase
activity. As shown in Fig. 5BI, cap-dependent translation mea-
sured by Renilla luciferase activity was inhibited at the G2/M
phase relative to the G1/S phase. This partial inhibition of
cap-dependent translation at the G2/M phase occurred inde-
pendently of the c-myc IRES and has been previously docu-
mented (reference 46 and references therein).
In direct contrast, translation of c-myc IRES-dependent
translation was increased at the G2/M phase relative to the
FIG. 5. Effects of hnRNP C on IRES-dependent translation of
c-myc mRNA at the G2/M phase. (A) Schematic diagrams of dicis-
tronic mRNA used in monitoring efficiency of cap- and c-myc IRES-
dependent translation in vivo and in vitro. The vectors contain the
CMV immediate-early enhancer/promoter (CMV E/P) directing tran-
scription in vivo and a T7 promoter (T7 pro.) directing transcription in
vitro. The transcription start sites through the CMV E/P and T7 pro-
moters are indicated by open and solid arrows, respectively. The di-
cistronic mRNA is composed of five consecutive elements: the 5 NTR
directing cap-dependent translation, Renilla luciferase gene (Rluc.
open box), c-myc IRES directing IRES-dependent translation, firefly
luciferase gene (Fluc. shaded box), and the 3 NTR. The mRNA
RM531F contains the complete c-myc IRES (nt 1 to 411) and the
N-terminal part of the c-Myc2 protein coding sequence up to nt 531
(solid box), which is fused to the firefly luciferase open reading frame.
The mRNA RM531(U‹C)F is a derivative of RM531F with the U-
to-C change in the heptameric U sequence of the c-myc IRES. The
restriction enzyme site HpaI used for linearization of the plasmids is
also designated by an arrow. (B) Relative translation activities of
dicistronic mRNAs at different cell cycle phases. The dicistronic con-
structs [pRM531F or pRM531(U‹C)F] and transfection control plas-
mid pCMV●SPORT-gal cotransfected into HeLa cells 12 h prior to
chemical treatments for synchronization. After synchronization, cells
were harvested and luciferase activity was measured. Panels BI and BII
represent relative Renilla and firefly luciferase activities at different cell
cycle phases, respectively. Shaded and open bars represent luciferase
activities of cells transfected with pRM531F and pRM531(U‹C)F,
respectively. For cap-dependent translation, Renilla luciferase activi-
ties were measured, and the relative value of each condition was
normalized to the Renilla luciferase activity of asynchronized (Asyn.)
cells transfected with pRM531F and that value was set to 1. For
IRES-dependent translation, firefly luciferase activities were mea-
sured, and the relative value of each condition was normalized to the
firefly luciferase activity of asynchronized cells transfected with
pRM531F and that value was set to 1. Transfection efficiency was also
determined for each luciferase value relative to that of the transfection
control -galactosidase activity. The lines represent standard deviation
values. Experiments were repeated at least three times to ensure re-
producibility. (C) Northern blot analysis of dicistronic mRNAs pro-
duced from cells transfected with pRM531F and pRM531(U‹C)F.
After harvesting synchronized cells, poly(A) RNAs were isolated and
then subjected to Northern blotting with a 32P-labeled probe corre-
sponding to the firefly luciferase gene. The positions of 28S and 18S
ribosomal RNAs are depicted as 28S and 18S in panel C. The human
ribosomal protein large subunit 32 (hRPL32) blot was used as an
internal control of poly(A) mRNAs. The arrow indicates the position
of dicistronic mRNAs. RNAs from asynchronized cells, G1/S-arrested
cells, and G2/M-arrested cells are shown on lanes 1 to 3, 4 to 6, and 7
to 9, respectively. RNAs from cells transfected with no plasmid,
pRM531F, and pRM531(U‹C)F were loaded on lanes 1, 4, and 7; 2,
5, and 8; and 3, 6, and 9, respectively. (D) The effect of hnRNP C on
translation through the c-myc IRES element. Translation reactions
were carried out as described in Materials and Methods. Variable
amounts of mock-translated RRL (lanes 1, 2, 3, 6, 7, and 8) and of
RRL containing presynthesized hnRNP C1 (lanes 2, 3, 4, 7, 8, and 9)
and PTB1 (lanes 5 and 10) were preincubated with the mRNA
RM531F (lanes 1 to 5) and RM531(U‹C)F (lanes 6 to 10) for 10 min
at 30°C. The amounts of RRL used in the RNA-protein interaction
reactions are indicated at the bottom. hnRNP C1-RRL, PTB1-RRL,
and Mock-RRL represent RRL containing proteins synthesized by in
vitro translation with hnRNP C1 mRNA, PTB1 mRNA and no
mRNA, respectively. After translation of the dicistronic reporter mR-
NAs [RM531F and RM531(U‹C)F], firefly and Renilla luciferase ac-
tivities were measured by using a dual-luciferase reporter assay system.
Shaded and open bars represent firefly and Renilla luciferase activities
of each dicistronic reporter mRNA [RM531F and RM531(U‹C)F],
respectively. For IRES-dependent translation, firefly luciferase activ-
ity, which was directed by mRNA RM531F, measured in the transla-
tion mixture with the addition of mock-translated RRL was arbitrarily
set to 1. For cap-dependent translation, Renilla luciferase activity,
which was directed by mRNA RM531F, measured in the translation
mixture with the addition of mock-translated RRL was arbitrarily set
to 1. Lines represent standard deviation values. (E) Protein levels of
hnRNP C, PTB, and actin in each in vitro translation mixture. Immu-
noblot analysis was used to monitor the protein levels of hnRNP C,
PTB, and actin in translation mixtures that contained both endog-
enously and exogenously synthesized proteins. About 50 g of total
proteins was used in each immunoblot analysis. The level of actin was
monitored to confirm that the amount of total protein was the same in
each immunoblot analysis. RRL mixtures were analyzed by using
monoclonal antibodies against hnRNP C (anti-hnRNP C), PTB (anti-
PTB), and actin (anti-actin), respectively.
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G1/S phase (Fig. 5BII). Interestingly, translation through the
wild-type c-myc IRES was increased at the G2/M phase by
about threefold, whereas translation through the mutant c-myc
IRES lacking the hnRNP C-binding site was increased by only
about 1.5-fold at the G2/M phase (Fig. 5BII). This marginal
activation of the mutant c-myc IRES at the G2/M phase may be
attributed to the general enhancement of IRES-dependent
translation at mitosis (see below). Alternatively, it could be
attributed to the residual activity of the mutated heptameric U
sequence. These data strongly suggest that the heptameric U
sequence plays an important role in the translation of c-myc
mRNA at the G2/M but not at the G1/S phase. The augmen-
tation of c-myc IRES activity by the heptameric U sequence at
the G2/M phase is most likely to occur through interaction with
hnRNP C, which becomes enriched in the cytoplasm at that
phase (see below).
To assess the level and integrity of the c-myc mRNA directly,
the dicistronic mRNAs were monitored by Northern blot anal-
ysis with a 32P-labeled DNA corresponding to the firefly lucif-
erase gene (Fig. 5C). Dicistronic mRNAs of expected sizes
were detected from all of the transfected cells (Fig. 5C, lanes
2, 3, 5, 6, 8, and 9). Similar intensities of mRNA bands were
detected from the wild-type and U-to-C mutant c-myc IRESs
at specific cell cycle phases (Fig. 5C, compare lanes 5 and 8
with lanes 6 and 9, respectively). The intensities of mRNA
bands at the G1/S phase were slightly higher than those at the
G2/M phase. From the Northern blot analysis, it appears that
the translation efficiency of the c-myc mRNA at the G2/M
phase compared with that at the G1/S phase may be higher
than the threefold measured by the firefly luciferase assay as
described above.
To demonstrate that hnRNP C augments translation of c-
myc IRES-dependent translation, the effect of the hnRNP C1
protein on the in vitro translation system (RRL) was investi-
gated by using the dicistronic mRNAs RM531F and
RM531(U‹C)F as reporters. Capped mRNA was generated
by in vitro transcription with T7 RNA polymerase. The pro-
teins hnRNP C1 and PTB1 (a negative-control RNA-binding
protein) were synthesized in RRL by in vitro translation of
mRNAs encoding hnRNP C1 and PTB1 and then added to in
vitro translation mixtures. Only a barely detectable amount of
hnRNP C protein exists in the RRL (Fig. 5E, lanes 1 and 5 of
anti-hnRNP C). Increased amounts of hnRNP C1 proteins
were detected by immunoblot analysis in RRL mixtures where
newly synthesized hnRNP C1 proteins were added (Fig. 5E,
lanes 2, 3, and 4, anti-hnRNP C). A large amount of PTB
protein exists in RRL (Fig. 5E, lanes 1 to 4, anti-PTB), and an
increased amount of PTB1 protein was detected by the addi-
tion of newly synthesized PTB1 protein (Fig. 5E, lane 5, anti-
PTB). The translation of firefly luciferase through the wild-
type c-myc IRES, which contains an hnRNP C-binding site,
was increased in a dose-dependent manner by the addition of
exogenous hnRNP C1 protein (Fig. 5D, lanes 1 to 4). In con-
trast, the translation of firefly luciferase through a mutant
c-myc IRES, which lacks an hnRNP C-binding site, was not
affected by the addition of exogenous hnRNP C1 protein (Fig.
5D, lanes 6 to 9). Moreover, the addition of exogenous PTB1
protein did not affect translation either through the wild-type
c-myc IRES (Fig. 5D, lane 5) or through the mutant c-myc
IRES (Fig. 5D, lane 10). The translation of cap-dependent
mRNA, which was monitored by Renilla luciferase activity, was
not influenced by the addition of either hnRNPC1 or PTB1
(Fig. 5D, lanes 1 to 10). These results strongly suggest that
hnRNP C augments the translation of c-myc mRNA via inter-
action with the heptameric U sequence of the c-myc IRES.
DISCUSSION
Cap-dependent translation is inhibited during the mitotic
phase of the cell cycle by hypophosphorylation of 4E-BP1, a
suppressor of eukaryotic initiation factor 4E function, and by
hyperphosphorylation of eukaryotic initiation factor 4GII (ref-
erence 46 and references therein). Therefore, an alternative
cap-independent mechanism of translation for mRNA encod-
ing unstable proteins is required at mitosis. Several viral and
cellular mRNAs has been shown to be functional at mitosis
through IRES-dependent mechanisms. For instance, poliovi-
rus (9), hepatitis C virus (26), ornithine decarboxylase (47),
and p58PITSLRE (12) IRESs are functional at the G2/M phase
where the switch from cap-dependent translation to IRES-
dependent translation may occur. This switch may be mediated
either indirectly through the increased availability of transla-
tion factors that are utilized in both cap-dependent and IRES-
dependent translations due to the inhibition of cap-dependent
translation at this phase or through the enrichment in the
cytoplasm of the specific factor(s) required for IRES function.
The c-Myc protein is involved in critical cellular processes,
including proliferation, transformation, and apoptosis (1, 45).
The c-Myc protein is required at different phases of the cell
cycle. For instance, the c-Myc protein plays a critical role in
G1/S progression (reference 45 and references therein) and is
necessary for DNA damage-induced apoptosis in the G2 phase
of the cell cycle (1). c-Myc is a very labile protein with a
half-life of 20 to 40 min (19) irrespective of the phase of the
cell cycle (21) and is degraded via the ubiquitin/26S protea-
some pathway (51). Therefore, c-myc mRNA should be trans-
lated under the conditions when most cellular mRNAs are not
functional. Indeed, c-myc mRNA contains an IRES element at
the 5 NTR that is functional during apoptosis when cap-
dependent translation is impaired (55).
Here we show that the c-Myc protein is synthesized through
an IRES element and that the IRES-dependent translation of
c-myc mRNA is augmented by hnRNP C, which is enriched in
the cytoplasm during the G2/M phase of the cell cycle (Fig.
5BII). The augmentation of c-myc IRES-dependent translation
is likely to be a way to maintain a constant level of c-Myc
protein throughout the cell cycle since cap-dependent transla-
tion (which is also used by c-myc mRNA) (57) of most of the
cellular mRNA decreases at the mitotic phase of the cell cycle
(Fig. 5BI) (reference 46 and references therein).
The boundary of the c-myc IRES was originally defined
between nt 363 and 94 upstream from the CUG364 start
codon (41). However, the authors did not show that the RNA
sequence between 363 and 94 upstream from CUG364 start
codon was sufficient for IRES function, even though it was
required for IRES activity (41). Stoneley and colleagues (56)
showed that the RNA sequence between nt 353 and 408 was
not essential for c-myc IRES activity by using dicistronic re-
porter mRNAs.
From our results, we suggest that the heptameric U se-
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quence residing downstream of the CUG364 initiation codon
plays an important role in IRES-dependent translation at the
G2/M phase (Fig. 5BII). The requirement of the heptameric U
sequence in the c-myc IRES-dependent translation seems to be
limited to the G2/M phase, since the wild-type c-myc IRES and
a mutant c-myc IRES lacking the heptameric U sequence
showed similar translational efficiency in cells arrested at the
G1/S phase as well as in asynchronized cells where interphase
cells predominate (Fig. 5BII). It should be noted that asynchro-
nized cells were used in the previous studies determining the
boundary of the c-myc IRES (41, 56). Therefore, the differ-
ences in the results are most likely due to differences in the
systems used in analyzing the IRES function of c-myc mRNA.
Here we show that the amounts of hnRNP C in the cyto-
plasm increase dramatically at the G2/M phase even though
most of the hnRNP C still remains in the nucleus (Fig. 4B and
C) (38). We also showed that hnRNP C interacts specifically
with the heptameric U sequence, and this interaction is re-
quired for the augmentation of IRES-dependent translation at
the G2/M phase. Moreover, we showed that the addition of
hnRNP C1 protein to an in vitro translation system (RRL)
significantly enhanced the function of the wild-type c-myc
IRES, which contains an hnRNP C-binding site, but not that of
a mutant c-myc IRES lacking a functional hnRNP C-binding
site. From these data we speculate that hnRNP C augments
IRES-dependent translation occurring at the G2/M phase
through an interaction with the heptameric U sequence of the
c-myc IRES.
The enrichment of hnRNP C in the cytoplasm at the G2/M
phase was shown by Millard et al. (38) through investigations
into RNA-binding proteins interacting with p27KIP1 mRNA,
which plays a key role in cell cycle regulation through the
inhibition of cyclin E-cdk2 (53). Cell cycle phase-dependent
fluctuation of hnRNP C in the cytoplasm may be attributed to
the redistribution of preexisting hnRNP C from the nucleus to
the cytoplasm and/or to the blockage of transportation of
newly synthesized hnRNP C to the nucleus. This study also
showed that the region including a U-rich element residing
about 40 nt upstream of the translation initiation codon is
required for efficient translation of p27KIP1 mRNA and that
hnRNP C and HuR specifically interact with the U-rich ele-
ment (38).
Intriguingly, there is a heptameric U sequence in the U-rich
element of p27KIP1 mRNA. However, the effect of changes in
the heptameric U sequence on hnRNP C binding has not yet
been investigated. Recently, Miskimins and colleagues showed
that p27KIP1 mRNA contains an IRES element (39), but the
effect of hnRNP C on the p27KIP1 IRES-dependent translation
was not investigated. It is possible that the functions of the
IRESs in both c-myc and p27KIP1, which play critical roles in
G1/S phase progression (35), are regulated by the same pro-
tein, namely hnRNP C. Moreover, Sella and colleagues sug-
gested that hnRNP C is also involved in PDGF2/c-sis IRES-
dependent translation (52). The authors showed that hnRNP C
interacts with a part of the PDGF2/c-sis 5NTR which contains
a differentiation-linked IRES element. In order to understand
the molecular mechanism of hnRNP C function, detailed roles
of hnRNP C in the cell cycle and differentiation need to be
further investigated.
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